Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
A Phase 1 Study of Lenzilumab in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)
Sponsor: Humanigen, Inc.
A PHASE1 clinical study on Chronic Myelomonocytic Leukemia (CMML), this trial is completed. The trial is conducted by Humanigen, Inc. and has accumulated 10 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Mar 2017 — Mar 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Humanigen, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .